Berenberg keeps EUR 3.60 target for Evotec stock

Published on 10/16/2026 at 16:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec results are due November 5, 2026. Evotec stock costs EUR 2.58 on October 16, 2026, up 2.06 percent versus the Xetra close.

Analyst view and valuation

On October 15, 2026, Berenberg retained its Hold rating and EUR 3.60 target for Evotec.
Evotec is scheduled to publish third-quarter and nine-month results on November 5, 2026.
Evotec stock costs EUR 2.58 at 4:03 p.m. CEST at Lang & Schwarz on October 16, 2026, 2.06 percent above the Xetra close of October 15, 2026.
Evotec carries a negative P/E of 2.33 and a market capitalization of USD 502.6 million as of October 16, 2026.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Pop-Art-Comic-Szene mit Wissenschaftler und Reagenzglas symbolisiert lebendig die Forschungswelt von Evotec SE, ISIN DE0005664809, Illustration mit AI erstellt.

Berenberg retained its Hold rating and EUR 3.60 price target for Evotec on October 15, 2026, according to MarketScreener. The target lies 39.53 percent above the EUR 2.58 price. Evotec stock was trading at EUR 2.58 at Lang & Schwarz on October 16, 2026, at 4:03 p.m. CEST, up 2.06 percent versus the Xetra close of October 15, 2026 at EUR 2.53.

Target distance is 39.53 percent

The Berenberg view leaves a measurable gap between the current German-market quotation and the analyst target. The firm kept the Hold rating rather than turning the positive reaction to Evotec's preliminary figures into an upgraded stance. Its note said that the recent results were stronger than expected, while short-term visibility remained limited.

Price stays below the yearly high

Evotec's intraday quote included a bid of EUR 2.58 and an ask of EUR 2.59 at 4:03 p.m. CEST. The stock stood 66.92 percent below its 52-week high of EUR 7.80 as of October 16, 2026. The latest quotation therefore places the share well below its yearly peak, even after the 2.06 percent move above the October 15 Xetra close.

Results date is November 5

Evotec is scheduled to publish its third-quarter and first-nine-month results on November 5, 2026, according to MarketScreener. The same report said Evotec had confirmed 2026 revenue guidance of EUR 570.0 million to EUR 610.0 million and adjusted EBITDA guidance of minus EUR 70.0 million to minus EUR 105.0 million. The figures are guidance, not reported results.

Comparison with peers

Evotec: plus 2.06 percent, P/E minus 2.33, market capitalization USD 502.6 million.
Sartorius (Xetra, EUR): minus 0.84 percent, P/E 91.73, market capitalization EUR 17.9 billion.
Qiagen (Xetra, EUR): plus 0.05 percent, P/E 23.75, market capitalization EUR 8.5 billion.

What the valuation shows

Evotec's negative P/E reflects losses rather than a conventional earnings valuation. Sartorius and Qiagen traded at positive earnings multiples on October 16, 2026, making the comparison a contrast in profitability as well as daily performance. Evotec's primary Frankfurt Prime Standard listing and its SDAX and TecDAX memberships are identified in the company's regulatory release.

Evotec price after the Xetra session

The next scheduled reporting date is the clearest calendar marker for investors watching whether the preliminary improvement carries into the complete figures. A separate company announcement on October 15, 2026 named Joanna Holbrook as chief scientific officer and a member of the management board effective November 1, 2026, according to Boerse Frankfurt. Evotec was trading at EUR 2.58 at Lang & Schwarz on October 16, 2026 at 4:03 p.m. CEST, 2.06 percent above the Xetra close of October 15, 2026 at EUR 2.53. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.